Adenosine A_2A receptor (A_2AR)

Adenosine A_2A receptor (A_2AR) Related Products (40):

By Type:	Pan (13) Selective (15)
By Effects:	Inhibitors (3) Agonists (9) Antagonists (26)

Cat. No.	Product Name	Effect	Purity

HY-N0092

Inosine	Agonist	99.67%
Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors.

HY-19532

ZM241385	Antagonist	99.45%
ZM241385 is a potent, high affinity and selective adenosine A_2a receptor (A_2AR) antagonist with a K_i value of 1.4 nM.

HY-14858

Derenofylline	Antagonist	99.93%
Derenofylline (SLV 320) is a potent, selective and orally active adenosine A₁ receptor antagonist, with K_i values of 1 nM, 200 nM and 398 nM for human A₁, A₃ and A_2A receptors respectively. Derenofylline suppresses cardiac fibrosis and attenuates albuminuria without affecting blood pressure in rats.

HY-103164

(E)-8-(3-Chlorostyryl)caffeine	Antagonist	99.4%
(E)-8-(3-Chlorostyryl)caffeine is a selective adenosine A_2A receptor antagonist. (E)-8-(3-Chlorostyryl)caffeine inhibits monoamine oxidase B (MAO-B) with a K_i value of 70 nM by a pathway that is independent of its actions on the A_2A receptor. (E)-8-(3-Chlorostyryl)caffeine has the potential for Parkinson's disease research.

HY-148088

M1069	Antagonist	98.04%
M1069 is a selective and orall active, dual A_2A/A_2B adenosine receptor antagonist with a selectivity of >100 fold against the A₁ and A₃ receptors. M1069 counteracts immune-suppressive mechanisms of adenosine, and exhibits anti-tumor activity.

HY-167905

ATL444	Antagonist
ATL444 is a adenosine receptor antagonist, with K_i values of 7.0, 2.5, 61.8, >1000 nM for rA₁AR, rA_2AAR, rA_2BAR, rA₃AR, respectively.

HY-106303

YT 146	Agonist
YT 146 is a potent agonist of A2 adenosine receptor (A2 AR) agonist. YT 146 causes a concentreation dependent cAMP accumulation, with the EC₅₀ of 1.5 nM. YT 146 has cardioprotective effects.

HY-158882

FLAC6
FLAC6 is a potent fluorinated detergent that can be used to solubilize membrane proteins (the native adenosine receptor A_2AR, a G protein-coupled receptor, and two native transporters AcrB and BmrA). FLAC6 can maintain the structural and functional integrity of different membrane proteins.

HY-103162

ANR94	Antagonist
ANR94 is a potent and selective adenosine A_2A receptor (AA_2AR) antagonist with an K_i of 46 nM for hAA_2AR. ANR94 has the potential for the research of Parkinson's disease.

HY-116800

FR194921	Antagonist	98.10%
FR194921 is a potent, selective and orally active and cross the blood-brain barrier Adenosine A1 antagonist with K_i value of 6.6, 5400 nM for A1, A2A, respectively. FR194921 shows cognitive-enhancing and anxiolytic activity.

HY-105017

Evodenoson	Agonist	99.74%
Evodenoson is a selective agonist of the A_2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α).

HY-144064

Adenosine receptor antagonist 2	Antagonist	99.37%
Adenosine receptor antagonist 2 is an orally active A2a/A2b adenosine receptor antagonist with IC₅₀s of 1 nM and 3 nM, respectively. Adenosine receptor antagonist 2 has anti-tumor activity.

HY-103175

PSB36	Antagonist	≥99.0%
PSB36 is a potent and selective antagonist of adenosine A₁ receptor, with K_is 0.12 nM, 187 nM, 552 nM, 2300 nM, and 6500 nM for rA₁, hA_2B, rA_2A, hA₃ and rA₃ receptors respectively. PSB36 can be used for the research of hyperalgesia.

HY-147907

Adenosine receptor inhibitor 1	Inhibitor	98.29%
Adenosine receptor inhibitor 1 is a potent and selective adenosine receptor (AR) inhibitor with K_i values of >1000, 68.5, >1000, >1000 nM for A₁AR, A_2AAR, A_2BAR, A₃AR, respectively. Adenosine receptor inhibitor 1 shows antinociceptive activity, anti-inflammatory effect and peripheral analgesic effect. Adenosine receptor inhibitor 1 has the potential for the research of cancer or neurodegenerative diseases.

HY-103174

MRS1334	Antagonist	≥99.0%
MRS1334 is a potent and selective human adenosine A₃ receptor antagonist with K_is of 2.69 nM, >100 nM, >100 nM for hA₃, rA₁, rA_2A, respectively. MRS1334 blocks the protective effect of Cl-IB-MECA leading to significant bradycardia and elevated ST segment. MRS1334 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103170

LUF5834	Agonist	99.8%
LUF5834 is a selective A_2B adenosine receptor (A2BR) partial agonist (EC₅₀ = 12 nM). LUF5834 is also a partial A₁/A_2A adenosine receptor agonist (lacking selectivity) with K_i values of 2.6 and 28 nM, respectively.

HY-N12422

A2AAR antagonist 2	Antagonist
3′-Methoxyfurano[4″,5″:3,4]chalcone (compound 2) is a selective A_2AAR antagonist (IC₅₀=33.5 nM) with high affinity. 3′-Methoxyfurano[4″,5″:3,4]chalcone is also a natural product obtained from the bark of Allium cepa L. 3′-Methoxyfurano[4″,5″:3,4]chalcone can promote T cell activation and can be used in cancer immunity research.

HY-147908

Adenosine receptor inhibitor 2	Inhibitor
Adenosine receptor inhibitor 2 (compound 14b) is a potent AR (adenosine receptor) inhibitor. Adenosine receptor inhibitor 2 shows dual affinity toward A₁/A_2A ARs with higher affinity for the A₁- than the A_2AAR. Adenosine receptor inhibitor 2 has K_i values of 52.2 nM for the A₁AR and 167 nM for the A_2AAR.

HY-147544

A1AR antagonist 5	Antagonist
A1AR antagonist 5 (compound 20) is a potent and selective A1AR (A1 adenosine receptor) antagonist, with a pIC₅₀ of 5.83 and a pK_i of 6.11.

HY-122231

MRS3558	Agonist
MRS3558 is a potent and selective A3AR agonist, with K_i values of 0.6 nM for humans and 0.9 nM for rats, making it suitable for research in the fields of neuropathic pain and anesthesia.

Name
Email *

	Sorry, but the email address you supplied was invalid.